BioInvent International announced that it has decided to terminate its current clinical Phase II study with BI-505 in multiple myeloma. The decision followed BioInvent’s review and discussion with the U.S. Food & Drug Administration (FDA), which put BI-505 on full clinical hold in November 2016.

The terminated trial, which was performed in collaboration with Penn Medicine, targeted a specific population of multiple myeloma patients undergoing autologous stem cell transplantation with high-dose melphalan.

BioInvent International AB is focused on developing a pipeline of antibody immunotherapeutics against cancer.

(Source: Business Wire)